ARTL Artelo Biosciences, Inc.
USHealthcareAs of 2026-07-10 16:00
Why ARTL matters now
Artelo Biosciences, Inc. (ARTL) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.08 with +5.88% on the session and $2.5M in market capitalization; recent performance reads 1-month -7.35% and YTD +3.28%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-3.0M, and EPS of $-4.00. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -275.9%.
The latest indexable market news headline is "Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—; recent insider activity includes Reyes Gregory filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.14
P/S
0.00
EV/EBITDA
0.51
DCF Value
$-1.22
FCF Yield
-275.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-1602.5%
ROA
-107.6%
ROIC
-157.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-3.0M | $-4.00 |
| Q4 2025 | $0.00 | $-4.2M | $-2.04 |
| FY 2025 | $0.00 | $-12.9M | $-5.47 |
| Q3 2025 | $0.00 | $-3.1M | $-1.32 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.14
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.